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The classical oral anticoagulants are increasingly being replaced in clinical practice by new 
antithrombotic drugs, which act by enabling direct inhibition of coagulation factor IIa (FIIa) or 
factor Xa (FXa). These drugs have multiple acronyms, including NOACs (new, non–vitamin K 
antagonist) or DOACs (direct oral anticoagulants), and currently include dabigatran (FIIa 
inhibitor), and rivaroxaban, apixaban, and edoxaban (FXa inhibitors). These drugs are approved 
for stroke prevention in patients with non-valvular atrial fibrillation and the prevention and 
treatment of venous thromboembolism. The "mantra" that DOACs do not require laboratory 
monitoring is not entirely correct because laboratory testing for drug effects is needed in many 
situations, because they influence hemostasis tests and in situations in which urgent measurement 
of DOACs is required. This should be very important to consider in the clinical situation for 
numbers of indications and increasing numbers of patients on DOACs therapy. The main aim of 
this article is to provide practical issues to general laboratory testing for DOACs, as well as to 
help avoid diagnostic errors associated with hemostasis testing. The assays for DOAC 
quantification must be available in medical centers on a whole day basis, to facilitate optimal drug 
management in conditions when things go wrong or in urgent cases of immediate reversal of 
anticoagulation or appropriate administration of a specific antidote. 
 






The direct oral anticoagulants (DOACs) including dabigatran (inhibits thrombin), 
rivaroxaban, apixaban, and edoxaban, (inhibits factor Xa) are increasingly replacing 
classic anticoagulant drugs vitamin K antagonists and heparin preparations for the 
following indications: for the prevention of stroke and systemic embolism in patients with 
non-valvular atrial fibrillation, for the primary prevention of venous thromboembolic 
events in patients undergoing elective surgery, for the treatment of deep vein thrombosis 
and pulmonary embolism, as well as for the prevention of these conditions reoccurring in 
adults (1,2). DOACs were introduced to overcome the limitations of Vitamin K 
antagonists (the narrow therapeutic range, inter- and intra-individual variability of 
anticoagulant response as a result of environmental and genetic factors, laboratory 
monitoring for dose adjustment, drug-drug interactions).  
DOACs have been tested in randomized clinical trials and proved safe and effective 
when administered at a fixed dose (based on patient characteristics) without the need for 
dose adjustment based on laboratory testing. Although the DOACs do not require routine 
coagulation monitoring, there are several situations in which DOACs anticoagulant 
activity should be measured (1). Nevertheless, measurements of their anticoagulant 
activity are useful in a specific situation or a specific patient, including 1) time before 
surgery or invasive procedure; 2) in case of adverse events (thrombosis or hemorrhage); 
3) patients with renal/liver disease; 4) whenever a possible interaction with other drugs is 
suspected; 5) in patients with extreme bodyweight; 6) to assess adherence to the therapy; 
7) before thrombolytic therapy in patients with stroke (3-6). Likewise, when urgent 
anticoagulation is required, DOACs measurement might be useful to ensure their 
appropriate administration and to prevent overuse of these expensive medications (7). 
The recommendations and consensus documents on laboratory testing of DOACs are 
consistent and guide clinicians in the decision-making process (4,8-10). Due to the high 
inter-individual variability in the response to DOAC, the assessment of DOAC 
concentrations cannot be based on the last intake (time-based approach). The reliable 
assays are established on a concentration-based approach but they must be readily 
available 24h/day, easy to perform with short turnaround time, and accurate for 
measurement of a wide range of concentrations (11,12). 
Since DOACs are removed from the circulation through the kidney or the liver, 
their use in patients with severe renal insufficiency or chronic liver disease is usually 
contraindicated. Much debate has been done over the last decade on the role that clinical 
laboratories may have in the management of patients on DOACs. Recommendations from 
regulatory authorities (FDA, EMA) have not been issued. Prescribing these drugs by 
clinicians is based on recommendations issued by scientific societies when available, but 
there is no uniform application. DOACs testing is poorly used because hospitals are not 




Laboratory testing for the DOACs 
While the relationship between DOACs levels and the clinical outcomes have been 
widely investigated and published, therapeutic ranges have not yet been defined (13). 
Instead of therapeutic ranges, it is much useful to inspect the concept of the “on-therapy” 
range (interval marked by the 5th percentile trough concentration and the 95th percentile 
peak concentration). Drug levels lower than the 5th percentile trough concentration could 
be considered as in the “below on-therapy” range, since those greater than the 95th 
percentile peak concentration may be considered to be “above on-therapy”. In this 
concept of the “on-therapy” range, the patients in steady-state plasma DOAC 
concentrations will have drug levels that fall within the on-therapy range at any time 
during treatment (14). 
The gold standard method for measurement of plasma DOACs concentrations 
(rivaroxaban, dabigatran, apixaban, edoxaban) is liquid chromatography/tandem mass 
spectrometry (LC-MS/MS) which requires expensive and sophisticated instrumentation, 
as well as skilled personnel, conditions that are unavailable to most routine clinical 
laboratories (15). Long turnaround time for test results would also make the method 
unsuitable for urgent testing in emergencies when you need to get a result within 30 
minutes. Therefore, to provide both routine and urgent assessment of DOACs, clinical 
laboratories are in a need of more practical tests.  
Routine coagulation assays and DOACs 
When considering the determination of anticoagulants in the laboratory, two 
concepts should be distinguished – monitoring and measuring. In the main “monitoring” 
concept the level of anticoagulation is assessed by dose adjustment based on results from 
laboratory testing. This concept is applied for vitamin K antagonists and unfractionated 
heparin monitoring therapy, using prothrombin time (PT) and activated partial 
thromboplastin time (aPTT). Monitoring anticoagulation with low molecular weight 
heparin (LMWH) does not require routine laboratory testing with anti-factor Xa assay, 
except for a special group of patients. Another concept is “measuring”, where the 
assessment of the level of anticoagulation or drug concentration in the blood is determined 
after administration of a fixed-dose. Although the “measuring” concept has been applied 
to DOACs, that does not mean laboratory testing is not necessary and useful in specific 
situations (12).  
The first laboratory testing in patients on DOACs included the routine coagulation 
assays - PT, aPTT, and thrombin time (TT), which are widely used in most clinical 
laboratories. PT, a PTT, and TT are tests that measure the activities of coagulation factors 
and overall function of the whole coagulation pathways – extrinsic, intrinsic, and 
common. The time of clot formation in these functional global tests can be a change in 




deficiencies, or the presence of antiphospholipid antibodies (15). Determination of PT, 
aPTT, and TT in patients on DOACs should only be used as a screening test that is aimed 
to confirm the existence or absence of an anticoagulant effect. These assays also cannot 
measure DOACs anticoagulant effect reliably, because of their poor sensitivity and 
specificity and lack of optimal dose-response relationships for monitoring DOACs (16). 
The results of PT, aPTT, and TT are dependent on the type of DOACs, the 
composition of commercial reagents, and the type of coagulometer used for testing. 
Likewise, the limitation of PT and aPTT are associated with their considerably different 
levels of responsiveness to increasing DOACs concentrations. The main fact is that 
normal PT and PTT don’t exclude DOAC activity and their prolongation doesn’t confirm 
DOACs action. A normal aPTT probably excludes above on-therapy concentrations, but 
not necessarily on-therapy or below on-therapy levels. PT is usually more sensitive than 
aPTT for rivaroxaban, and normal PT probably excludes above on-therapy levels of 
rivaroxaban and edoxaban. For apixaban, PT and aPTT have normal values and are not 
useful. For dabigatran PT and aPTT should not be used, only a normal TT excludes 
clinically relevant existence of the drug in circulation (17). Furthermore, unclottable 
prolongation of TT may occur in patients taking 150 mg dabigatran twice daily, because 
of the excessive responsiveness. As a result of all the above, the use of PT or PTT to 
evaluate DOACs activity could cause misinterpretations of routine coagulation assays, 
especially by non-expert clinicians. Consequently, only a normal TT excludes clinically 
relevant levels of dabigatran (18,19). The effect of dabigatran, rivaroxaban, apixaban, and 
edoxaban on global and specific coagulation assays to below, within, and above typical 
'on-therapy' range is shown in Table I. 
Specific assays for DOACs 
The DOACs anticoagulant effect should only be qualitatively validated with routine 
coagulation tests, PT, aPTT, and TT, but these tests should not be used to adjust doses 
and dosing intervals. The specific, second-line tests for DOACs which can be performed 
in specialized coagulation laboratories include diluted thrombin time (dTT), ecarin 
clotting time (ECT), and anti-Xa assays.  
The chromogenic anti-factor Xa assay can be used for the quantification of 
anticoagulant DOACs-factor Xa inhibitors activity (rivaroxaban, apixaban, and 
edoxaban). The dTT and ECT assays should be applied to measure the dabigatran 
anticoagulant effect. Direct measurement of drug plasma concentrations with LC-MS/MS 
is possible in a small number of laboratories and cannot be used in making therapeutic 
decisions (12,20). 
Diluted thrombin time (dTT). TT is a coagulometric test very sensitive to dabigatran 
and the anticoagulant effect could be measured only with diluted TT. Dilution of patient 
plasma in dTT test provides an adequate response to dabigatran, with a clotting time 




taking dabigatran 150 mg twice daily, twofold dTT prolongation over the normal clotting 
time can be detected, thus the clotting time prolongation of dTT is proportional to the 
inhibitory activity of dabigatran. The dTT test is commercially available from different 
manufacturers (12,19). The lowest concentration of DOACs that allows a safe surgical or 
invasive procedure is unknown and should be derived only from clinical trials. Most 
recommendations advise that DOAC levels of less than 50 ng/ml can be considered 
relatively safe, and this cutoff should be pragmatically adopted (12). 
 
Table I  Effect of Dabigatran, Rivaroxaban, Apixaban and Edoxaban on routine and specific  
 coagulation assays to below, within, and above typical 'on-therapy' range (18) 
Tabela I  Uticaj dabigatrana, rivaroksabana, apiksabana i edoksabana na rutinske i  
 specifične koagulacione testove u odnosu na očekivani terapijski opseg (unutar,  







Dabigatran Rivaroxaban Apixaban Edoxaban 
aPTT 
Below Normal/Prolonged Normal limits Normal limits Normal limits 
Within Prolonged Normal/Prolonged Normal/Prolonged Normal limits 
Above Prolonged Normal/Prolonged Prolonged Normal/Prolonged 
 
PT 
Below Normal limits Normal limits Normal limits Normal limits 
Within Normal/Prolonged Normal/Prolonged Normal/Prolonged Normal/Prolonged 
Above Normal/Prolonged Normal/Prolonged Normal/Prolonged Normal/Prolonged 
 
TT 
Below Prolonged Normal Not indicated Not indicated 
Within Prolonged/Out of range Normal Not indicated Not indicated 




Below Normal/Prolonged Not indicated Not indicated Not indicated 
Within Prolonged Not indicated Not indicated Not indicated 
Above Prolonged Not indicated Not indicated Not indicated 
 
Anti-Xa 
Below Not indicated Normal/Increased Normal/Increased Normal/Increased 
Within Not indicated Increased Increased Increased 





Ecarin clotting time (ECT). ECT based on ecarin, a snake venom extract, able to 
convert prothrombin into thrombin, is another commercial assay that can be used for 
dabigatran. The inhibition by dabigatran can be measured by a chromogenic substrate or 
clotting method (18, 21). For dabigatran, a concentration of 30 ng/mL is considered safe 
for surgery in the case of intervention with bleeding risk. Therefore, if the concentration 
is higher than 30 ng/mL, the intervention should be delayed. The use of specific 
coagulation tests may also guide the clinician in the use of idarucizumab, the dabigatran 
antidote. It has been suggested that if the plasma concentration of dabigatran is below 50 
ng/mL in a bleeding patient, a reversal agent should not be administered (22). 
Anti–factor Xa assays (Anti-Xa) 
The Anti-Xa test is used as a method of choice for measuring anti-factor Xa activity 
in patients treated with unfractionated (UFH) or LMWH. Anti-factor Xa activity of 
DOACs (rivaroxaban, apixaban, or edoxaban), in a dose-dependent manner, can be 
measured by a specific chromogenic substrate (23,24). The presence of clinically relevant 
plasma concentrations of anti-factor Xa inhibitors can be measured by an anti-Xa test, 
using plasma calibrators commercially available, mandatory for each specific DOAC. 
Plasma drug concentration derived from the calibration curve, acquire proper result 
interpretation in regards to the timing of drug intake. These tests are applied to various 
commercial coagulometers in clinical laboratories (12,15). In practice, each laboratory 
requires the use of specific reagents, calibrators, and controls for each drug, and needs to 
implement at least three different tests for each of the currently available anti-Xa drugs. 
The laboratory professionals will also need to maintain the coagulation analyzer 
calibrated and monitored (by internal quality controls) for all these tests, perhaps 24 hours 
a day and 365 days a year, since urgent assessment may be required. That is why 
regulatory authorities should urgently approve the use of these assays for a patient on 
DOACs in special conditions, and guidelines on how and when to do DOAC testing 
should be urgently implemented in local hospitals (25,26). 
Recommendations for laboratory measurement of DOACs based on clinical 











Table II  Suggestions for laboratory measurement of DOAC based on clinical objective (25) 
Tabela II Preporuke za laboratorijsko određivanje direktnih oralnih antikoagulanasa  
 zasnovane na kliničkom cilju (25) 
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Normal TT likely 
excludes clinically 








Normal aPTT likely 
excludes excess drug 
levels; 
Only dTT, ECT is sutable 
for quantitation 
Rivaroxaban Anti-Xa 
Normal anti-Xa activity 
likely excludes 






Normal PT likely excludes 
excess drug levels; 
Only anti-Xa is suitable 
for quantitation 
Apixaban Anti-Xa 
Normal anti-Xa activity 
likely excludes 








General laboratory testing in patients on DOACs    
Laboratory monitoring in patients on DOACs is of great importance to guide 
appropriate anticoagulation therapy and ensure drug safety. DOACs are cleared from 
circulation by kidney (dabigatran 80%, edoxaban50%, rivaroxaban 30%, and apixaban 
25%, respectively) or liver (apixaban 75%, rivaroxaban 66%, edoxaban50%, dabigatran 
20%). Therefore, acute renal or liver impairment may also substantially impair the blood 
levels of all DOACs and expose the patients to a significant risk of overcoagulation or 
undercoagulation. (2,27). The most commonly used laboratory profile includes general 
laboratory tests for screening renal and hepatic function and assessing bleeding risk. The 
frequency of laboratory testing depends on individual patient characteristics (monthly or 
every 3-6 months) and include age, comorbidities, renal/liver function, and concurrent 




because all DOACs are partially eliminated through the kidneys. Renal function should 
be estimated based on serum creatinine (SCr) for creatinine clearance calculation 
(Cockcroft-Gault equation or estimated glomerular filtration rate (eGFR)). To ensure 
appropriate dosing and prevent bleeding complications periodical routine measuring of 
SCr is required (28). Because the rate of renal elimination varies among the different 
DOACs, fluctuations in renal function can potentially lead to considerable bleeding 
complications. 
A laboratory analyzes of liver function assessment (aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), bilirubin, alkaline phosphatase, PT) should be 
determined at the beginning of therapy and periodically afterwards, to detect any 
significant changes in hepatic function. Estimation of hepatic function is required yearly 
for healthy patients, while more frequent monitoring is necessary for patients with risk of 
liver disease (at least every 6 months). In addition to the data for monitoring liver 
function, the Child-Pugh scoring system could be helpful to predict mortality in patients 
with cirrhosis, using five clinical and laboratory criteria to categorize patients (serum 
bilirubin, serum albumin, ascites, neurological disorder, and prothrombin time) (29,30). 
Measurement of the complete blood count (CBC) is essential at the baseline and during 
initiation of the DOACs therapy, at least yearly thereafter, or more repeatedly in patients 
with bleeding symptoms.  
Effect of direct oral anticoagulants on hemostatic parameters 
Hemostasis tests are often requested by clinicians during oral anticoagulation 
therapy, especially parameters for thrombophilia screening (antithrombin, protein C, 
protein S, activated protein C resistance, lupus anticoagulant, factor VIII). A large number 
of studies have shown that DOACs may be a reflection of inappropriate testing during 
anticoagulant therapy, resulting in misinterpretation of the results (31,32). A recent check 
of clinical practice indicates that up to 1/3 of samples destined for thrombophilia 
investigations are from patients on oral anticoagulant therapy, and thus is representing 
the high potential for diagnostic error. The proper timing of test orders for thrombophilia 
screening is very important, and whenever possible testing should be performed after 
discontinuation of the DOACs treatment (4-5 days) (35). 
Antithrombin 
If the patient is taking dabigatran and the target enzyme used for antithrombin 
measurement is thrombin, antithrombin activity will be overestimated, as thrombin 
activity will be inhibited not only by antithrombin but also by dabigatran. The same 
overestimation will occur when the anti-FXa drug is taken, and the target enzyme used 
for testing is FXa. The extent of overestimation could be such to mask the diagnosis in 
patients with congenital heterozygous antithrombin deficiency. To avoid these 




be performed with methods using FXa as the target enzyme. Conversely, methods using 
thrombin as the target enzyme should be used for patients on anti-FXa drugs (12, 33). 
Lupus anticoagulants  
The interpretation of LA detection in patients taking DOACs using phospholipid-
dependent tests (aPTT and dRVVT) may be problematic. There are some reports in the 
literature on special procedures used to try to overcome the interference of DOAC on LA 
testing. However, considering the reagents and methods are not standardized, no 
procedure can be recommended for general use to search for LA in patients on DOAC. 
When the laboratory diagnosis of LA is strictly needed, temporarily switching the patient 
from DOAC to LMWH (if the brand used does not interfere with LA testing) could be a 
helpful alternative (34,35). 
The effects of DOACs on the hemostatic parameters are shown in Table III. 
 
Table III Effects of direct oral anticoagulants on the results of hemostatic parameters (12) 




Risk for misdiagnosis 
Antithrombin activity Overestimation 
Absence in antithrombin deficiency 
False-negative 
Protein C activity Overestimation 
Absence in PC deficiency 
False-negative 
Protein S activity Overestimation 
Absence in PS deficiency 
False-negative 





patients on dabigatran 
Hypofibrinogenemia 
False-positive 
Activated protein C 
resistance (APC ratio) 
Underestimation 




Difficult to interpret the 
result 









Routine coagulation assays are widely available, rapid, and inexpensive but limited 
in their accuracy for measuring DOACs drug levels. Specific assays can accurately 
quantify the drugs however they are only available in specialized coagulation laboratories 
and are more expensive. In these circumstances, appropriate recommendations for 
DOACs laboratory testing include a combination of routine and second-line hemostasis 
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Praktični aspekti u određivanju antikoagulantnog 
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Nova generacija oralnih antikoagulantnih lekova omogućava direktnu inhibiciju FIIa ili 
FXa, i sve više zamenjuje klasične antikoagulanse u kliničkoj praksi za različita stanja. Ovi lekovi 
su označeni sa nekoliko akronima, uključujući NOAC, DOAC, i odnose se na nove (ne-vitamin 
K antagoniste) i direktne oralne antikoagulanse, a trenutno uključuju dabigatran (FIIa inhibitor), 
i rivaroksaban, apiksaban i edoksaban (FXa inhibitori) . Direktni oralni antikoagulantni lekovi 
odobreni su za prevenciju moždanog udara kod pacijenata sa ne-valvularnom atrijalnom 
fibrilacijom i za prevenciju i lečenje venskog tromboembolizma. „Mantra” da direktni oralni 
antikoagulantni lekovi ne zahtevaju laboratorijsko praćenje ne može se prihvatiti u mnogim 
kliničkim situacijama. Štaviše, pošto ovi lekovi „ne zahtevaju” laboratorijsko praćenje, neki 
kliničari su to prihvatili kao da ne utiču na testove u hemostazi. Postoji više situacija u kojima je 
potrebno rutinsko i hitno određivanje DOAC-a, pri čemu će se broj laboratorijskih zahteva 
povećavati u budućnosti jer sve više zamenjuju konvencionalne antikoagulanse za sve veći broj 
indikacija, kod sve većeg broja pacijenata. Glavni cilj ovog rada je da odgovori na praktična 
pitanja u opštem laboratorijskom ispitivanju DOAC-a, kao i da pomogne u uklanjanju i smanjenju 
dijagnostičkih grešaka povezanih sa ispitivanjem hemostaze. Testovi za kvantifikaciju DOAC-a 
moraju biti dostupni u medicinskim centrima 24 sata, kako bi se olakšalo optimalno lečenje u 
uslovima kada stvari pođu po zlu ili u hitnim slučajevima trenutnog ukidanja antikoagulantne 
terapije ili odgovarajuće primene specifičnog antidota. 
 
Ključne reči: DOAC, rivaroksaban, dabigatran, apiksaban, laboratorijsko praćenje 
 
 
 
